What are mTOR inhibitor drugs?

mTOR inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting mTOR (mammalian target of rapamycin)). 10 are currently marketed, with 11 more in clinical development.

What are the marketed mTOR inhibitor drugs?

Marketed mTOR inhibitor drugs include mTOR inhibitor (everolimus), Percutaneous sirolimus, Everolimus Tab., Everolimus Tablets, Rapamune® (Sirolimus), Drug conversion to sirolimus.

mTOR inhibitor

10 marketed 10 in Phase 3 1 in Phase 2

This page covers all mTOR inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting mTOR (mammalian target of rapamycin), mTOR (mechanistic target of rapamycin), mTOR (mTORC1).

Targets

mTOR (mammalian target of rapamycin) · mTOR (mechanistic target of rapamycin) · mTOR (mTORC1) · mTORC1 · mTOR · mTORC1/2

Marketed (10)

mTOR inhibitor (everolimus) · Hannover Medical School · Oncology
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
Percutaneous sirolimus · Children's Hospital of Fudan University · Dermatology
Percutaneous sirolimus is a topical formulation of the immunosuppressant sirolimus delivered through the skin to inhibit mTOR signaling and suppress immune cell proliferation.
Everolimus Tab. · Chong Kun Dang Pharmaceutical · Oncology
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
Everolimus Tablets · Shandong Suncadia Medicine Co., Ltd. · Oncology; Immunology
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
Rapamune® (Sirolimus) · Wyeth is now a wholly owned subsidiary of Pfizer · Immunology
Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation, thereby suppressing immune cell activation and reducing organ rejection.
Drug conversion to sirolimus · Hospital do Rim e Hipertensão · Immunology / Transplantation
Sirolimus is an mTOR inhibitor that suppresses T-cell proliferation and immune activation to prevent organ rejection.
Sirolimus Tab. · Chong Kun Dang Pharmaceutical · Immunology, Oncology
Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation.
Rapamune (sirolimus/rapamycin) · University at Buffalo · Immunology, Oncology
Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation, thereby suppressing immune cell activation and reducing organ rejection.
Sirolimus Oral Product · Shanghai Children's Medical Center · Immunology; Oncology
Sirolimus inhibits mTOR (mammalian target of rapamycin), a key regulator of cell proliferation and immune cell activation.
Sirolimus (SIR) · H. Lee Moffitt Cancer Center and Research Institute · Oncology; Immunology
Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation.

Phase 3 pipeline (10)

Drug: Everolimus · Grupo Espanol de Tumores Neuroendocrinos · Oncology
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
LAM group · GlaxoSmithKline · Rare Pulmonary/Oncology
LAM group refers to a class of compounds targeting lymphangioleiomyomatosis-related pathways, likely inhibiting mTOR signaling to reduce abnormal smooth muscle cell proliferation.
Low-dose sirolimus · Icahn School of Medicine at Mount Sinai · Immunology
Low-dose sirolimus inhibits mTOR signaling to suppress immune cell proliferation and promote regulatory T cell differentiation.
Sirolimus (Rapamune®) · Wyeth is now a wholly owned subsidiary of Pfizer · Immunology, Oncology
Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation.
Everolimus (Afinitor) tablets · Exelixis · Oncology
Everolimus inhibits mTOR (mammalian target of rapamycin), a protein kinase that controls cell growth and proliferation.
Rapamycin-calcitriol combination · National Taiwan University Hospital · Oncology
Rapamycin-calcitriol combination inhibits the mammalian target of rapamycin (mTOR) and vitamin D receptor (VDR) pathways.
Sirolimus Topical Cream · Melanoma and Skin Cancer Trials Limited · Oncology
Sirolimus is an mTOR inhibitor that suppresses immune cell proliferation and angiogenesis when applied topically to skin lesions.
Temsirolimus (CCI-779) · Pfizer · Oncology
Temsirolimus is a mTOR inhibitor that blocks the mTOR pathway, which is involved in cell growth and proliferation.
Everolimus (Afinitor®) · Odense University Hospital · Oncology
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that controls cell growth and proliferation.
Everolimus (Certican) · Novartis · Immunology, Oncology
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.

Phase 2 pipeline (1)

ARQ 092 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Oncology
ARQ 092 is a potent and selective inhibitor of mTORC1/2.